» Articles » PMID: 15657354

Epigenetic Regulation of O6-methylguanine-DNA Methyltransferase Gene Expression by Histone Acetylation and Methyl-CpG Binding Proteins

Overview
Journal Mol Cancer Ther
Date 2005 Jan 20
PMID 15657354
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Transcriptional silencing of the DNA repair gene, O6-methylguanine-DNA methyltransferase (MGMT) in a proportion of transformed cell lines is associated with methylated CpG hotspots in the MGMT 5' flank. The goal of the study was to evaluate the mechanism by which CpG methylation of theMGMT promoter region influenced silencing of the gene. Analysis of histone acetylation status in two regions of the promoter using chromatin immunoprecipitation assay showed that a higher level of histone acetylation was associated with expression in three MGMT-expressing cell lines (HeLa CCL2, HT29, and Raji) compared with three MGMT-silenced cell lines (HeLa S3, BE, and TK6). To determine how the modulation of CpG methylation and histone acetylation influenced MGMT expression, we exposed the cells to 5-aza-2'deoxycytidine (5-Aza-dC), inhibitor of DNA methylation, which strongly up-regulated MGMT expression in three MGMT-silenced cell lines whereas trichostatin A, inhibitor of histone deacetylase, weakly induced MGMT. However, combined treatment with 5-Aza-dC and trichostatin A significantly up-regulated MGMT RNA expression to a greater extent than in cells treated with either agent alone suggesting that histone deacetylation plays a role in MGMT silencing but that CpG methylation has a dominant effect. Consistent with enhanced MGMT expression, 5-Aza-dC increased the association of acetylated histone H3 and H4 bound to the MGMT promoter. Chromatin immunoprecipitation analysis of methyl-CpG binding domain containing proteins detected a greater amount of MeCP2, MBD1, and CAF-1 bound to the MGMT promoter in MGMT-silenced cells. Our findings implicate specific MBD proteins in methylation-mediated transcriptional silencing of MGMT.

Citing Articles

The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.

Guven M, Taspinar F, Denizler-Ebiri F, Castresana J, Taspinar M Med Oncol. 2023; 40(8):223.

PMID: 37403006 DOI: 10.1007/s12032-023-02079-6.


New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.

Zhang C, Sheng Y, Sun X, Wang Y Cancer Metastasis Rev. 2023; 42(3):891-925.

PMID: 37368179 PMC: 10584725. DOI: 10.1007/s10555-023-10113-2.


The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy.

Psilopatis I, Garmpis N, Garmpi A, Vrettou K, Sarantis P, Koustas E Cancers (Basel). 2023; 15(8).

PMID: 37190151 PMC: 10137219. DOI: 10.3390/cancers15082222.


2-Pyridin-4-yl-methylene-beta-boswellic Acid-A Potential Candidate for Targeting O-Methylguanine-DNA Methyltransferase Epi-transcriptional Reprogramming in KRAS G13D-Microsatellite Stable, G12V-Microsatellite Instable Mutant Colon Cancer.

Qayum A, Singh J, Kumar A, Shah S, Srivastava S, Kushwaha M ACS Pharmacol Transl Sci. 2022; 5(5):306-320.

PMID: 35592435 PMC: 9112411. DOI: 10.1021/acsptsci.1c00228.


XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA.

Hirota K, Ooka M, Shimizu N, Yamada K, Tsuda M, Ibrahim M Genes Cells. 2022; 27(5):331-344.

PMID: 35194903 PMC: 9310723. DOI: 10.1111/gtc.12929.